Asset Details
Do you wish to reserve the book?
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
Do you wish to request the book?
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
2018
Overview
The goal of cancer immunotherapy is to stimulate the host immune system to attack malignant cells. Antibody-dependent cellular cytotoxicity (ADCC) is a pivotal mechanism of antitumor action of clinically employed antitumor antibodies. IL-15 administered to patients with metastatic malignancy by continuous i.v. infusion at 2 μg/kg/d for 10 days was associated with a 38-fold increase in the number and activation status of circulating natural killer (NK) cells and activation of macrophages which together are ADCC effectors. We investigated combination therapy of IL-15 with rituximab in a syngeneic mouse model of lymphoma transfected with human CD20 and with alemtuzumab (Campath-1H) in a xenograft model of human adult T cell leukemia (ATL). IL-15 greatly enhanced the therapeutic efficacy of both rituximab and alemtuzumab in tumor models. The additivity/synergy was shown to be associated with augmented ADCC. Both NK cells and macrophages were critical elements in the chain of interacting effectors involved in optimal therapeutic responses mediated by rituximab with IL-15. We provide evidence supporting the hypothesis that NK cells interact with macrophages to augment the NK-cell activation and expression of FcγRIV and the capacity of these cells to become effectors of ADCC. The present study supports clinical trials of IL-15 combined with tumor-directed monoclonal antibodies.
Publisher
National Academy of Sciences
Subject
/ Alemtuzumab - administration & dosage
/ Animals
/ Antibodies, Monoclonal - immunology
/ Antibody-Dependent Cell Cytotoxicity - drug effects
/ Antibody-Dependent Cell Cytotoxicity - immunology
/ Antineoplastic Combined Chemotherapy Protocols - pharmacology
/ Cancer
/ Cells
/ Female
/ Humans
/ Interleukin-15 - administration & dosage
/ Killer Cells, Natural - drug effects
/ Killer Cells, Natural - immunology
/ Leukemia
/ Lymphoma
/ Male
/ Mice
/ Rituximab - administration & dosage
/ Toxicity
/ Tumors
